Julian Baker’s Kiniksa Pharmaceuticals KNSA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $181M | Buy |
2,834,643
+8,397
| +0.3% | +$436K | 0.91% | 18 |
|
|
2026
Q1 | $136M | Hold |
2,826,246
| – | – | 0.78% | 17 |
|
|
2025
Q4 | $117M | Buy |
2,826,246
+1,577
| +0.1% | +$63.3K | 0.68% | 23 |
|
|
2025
Q3 | $110M | Hold |
2,824,669
| – | – | 0.79% | 15 |
|
|
2025
Q2 | $78.2M | Buy |
2,824,669
+6,346
| +0.2% | +$162K | 0.76% | 17 |
|
|
2025
Q1 | $62.6M | Hold |
2,818,323
| – | – | 0.69% | 17 |
|
|
2024
Q4 | $55.7M | Hold |
2,818,323
| – | – | 0.6% | 22 |
|
|
2024
Q3 | $70.4M | Hold |
2,818,323
| – | – | 0.73% | 21 |
|
|
2024
Q2 | $52.6M | Buy |
2,818,323
+8,746
| +0.3% | +$164K | 0.67% | 23 |
|
|
2024
Q1 | $55.4M | Hold |
2,809,577
| – | – | 0.7% | 23 |
|
|
2023
Q4 | $49.3M | Hold |
2,809,577
| – | – | 0.56% | 23 |
|
|
2023
Q3 | $48.8M | Hold |
2,809,577
| – | – | 0.28% | 22 |
|
|
2023
Q2 | $39.6M | Buy |
2,809,577
+10,000
| +0.4% | +$134K | 0.23% | 28 |
|
|
2023
Q1 | $30.1M | Hold |
2,799,577
| – | – | 0.16% | 30 |
|
|
2022
Q4 | $41.9M | Hold |
2,799,577
| – | – | 0.25% | 27 |
|
|
2022
Q3 | $35.9M | Hold |
2,799,577
| – | – | 0.24% | 32 |
|
|
2022
Q2 | $27.1M | Hold |
2,799,577
| – | – | 0.15% | 39 |
|
|
2022
Q1 | $27.8M | Hold |
2,799,577
| – | – | 0.16% | 44 |
|
|
2021
Q4 | $33M | Hold |
2,799,577
| – | – | 0.16% | 45 |
|
|
2021
Q3 | $31.9M | Hold |
2,799,577
| – | – | 0.14% | 50 |
|
|
2021
Q2 | $39M | Hold |
2,799,577
| – | – | 0.17% | 44 |
|
|
2021
Q1 | $51.8M | Hold |
2,799,577
| – | – | 0.22% | 39 |
|
|
2020
Q4 | $49.5M | Hold |
2,799,577
| – | – | 0.19% | 35 |
|
|
2020
Q3 | $42.9M | Hold |
2,799,577
| – | – | 0.17% | 37 |
|
|
2020
Q2 | $71.3M | Hold |
2,799,577
| – | – | 0.31% | 26 |
|
|
2020
Q1 | $43.3M | Hold |
2,799,577
| – | – | 0.27% | 28 |
|
|
2019
Q4 | $31M | Hold |
2,799,577
| – | – | 0.16% | 40 |
|
|
2019
Q3 | $23.8M | Hold |
2,799,577
| – | – | 0.16% | 38 |
|
|
2019
Q2 | $37.9M | Sell |
2,799,577
-200,423
| -7% | -$3.11M | 0.26% | 36 |
|
|
2019
Q1 | $54.2M | Hold |
3,000,000
| – | – | 0.35% | 30 |
|
|
2018
Q4 | $84.3M | Hold |
3,000,000
| – | – | 0.69% | 15 |
|
|
2018
Q3 | $76.5M | Hold |
3,000,000
| – | – | 0.5% | 22 |
|
|
2018
Q2 | $52M | Buy |
+3,000,000
| New | +$54.3M | 0.39% | 24 |
|
Other funds holding KNSA
RCMNY
TCM
SSC
Julian Baker's KNSA Position: Q2 2026 in Review
Julian Baker increased its Kiniksa Pharmaceuticals (KNSA) stake by 0.3% in Q2 2026, buying an estimated $436K and bringing the position to 2,834,643 shares worth $181M. The position accounts for 0.91% of the portfolio, ranked #18.
Julian Baker first reported a position in KNSA in Q2 2018 and has held it in 33 quarters since. 265 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.
- Julian Baker held 2,834,643 shares of Kiniksa Pharmaceuticals worth $181M as of Q2 2026.
- Julian Baker bought 8,397 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $436K.
- Kiniksa Pharmaceuticals made up 0.91% of Julian Baker's portfolio in Q2 2026, its #18 holding.
- Julian Baker first reported a position in Kiniksa Pharmaceuticals in Q2 2018 and has held it in 33 quarters since.
- 265 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.
Based on Baker Bros. Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.